From 1 November 2020, Prezista® (darunavir) 150 mg tablets, used in combination with other antiretroviral agents for HIV treatment, will be discontinued for supply in Australia and removed from the Pharmaceutical Benefits Scheme.
This delisting may affect HIV treatment-experienced paediatric patients aged 6 years and older – where Prezista® (darunavir) 150 mg strength is typically used in combination treatment.
The pharmaceutical provider, Janssen-Cilag Pty Ltd (‘Janssen’), make note that the discontinuation of the 150 mg dosage form does not impact on the supply of the 600 mg and 800 mg tablet strengths.
Therefore, if you are someone (or working with persons) who will be affected with this change, we strongly encourage you to start consulting with your healthcare professional (prescribing S100 physician or treatment officer).
Related links
- Consumer medicine information: Prezista Tablets — NPS MedicineWise
